In a recent study published in the journalFrontiers in Medicine, researchers analyzed data from a large cohort of inflammatory bowel disease (IBD) patients and compared the risk and frequency of
In a recent study published in the journalFrontiers in Medicine, researchers analyzed data from a large cohort of inflammatory bowel disease (IBD) patients and compared the risk and frequency of
by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA
by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA
by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f
by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f
byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co
byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co
byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low
byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low
by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11
by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11
by Rutgers Cancer Institute of New JerseyCredit: Pixabay/CC0 Public DomainGenetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, c
by Rutgers Cancer Institute of New JerseyCredit: Pixabay/CC0 Public DomainGenetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, c
by Center for Genomic RegulationCredit: CC0 Public DomainBased on the largest study of cancer patients of its kind, scientists have created a new way of classifying tumours. Clinicians can use genome
by Center for Genomic RegulationCredit: CC0 Public DomainBased on the largest study of cancer patients of its kind, scientists have created a new way of classifying tumours. Clinicians can use genome
byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan
byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan
by Children's Cancer Institute AustraliaCredit: CC0 Public DomainToday, OncoTartis, Inc. and Children's Cancer Institute jointly announced the publication of two research manuscripts in a lead
by Children's Cancer Institute AustraliaCredit: CC0 Public DomainToday, OncoTartis, Inc. and Children's Cancer Institute jointly announced the publication of two research manuscripts in a lead
byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b
byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b